Word: interleukins
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...interactions between helper T cells and APCs to develop antibody drugs against lupus and RA. Their anti-RA antibody selectively switches off T cells involved in autoimmune responses by binding the CD4 molecule on their surfaces. Amgen, of Thousand Oaks, Calif., has developed a drug that works by blocking Interleukin-1, another molecule that promotes inflammation...
...been enough success with interferon, says Dr. Ronald Blum, director of the Beth Israel Cancer Center in New York City, to make the immune-boosting drug be considered a standard of care. And, he adds, "for those who can withstand the short but very toxic inpatient treatment program, interleukin-2 can lead to significant reductions in tumor size." In most advanced cases, however, all that these and other valiant efforts can do is buy a few months, maybe a couple of years at the outside...
...HELP More hope on the AIDS front. A new study shows that adding the immune-system stimulant interleukin-2 to the usual brew of AIDS drugs can more than double T-cell counts in patients infected with HIV. Plus, in a surprise for researchers, blood levels of HIV dropped slightly too. Both findings are decidedly encouraging, though it's too early to know for sure whether revving up T cells this way will delay the onset of full-blown AIDS. And there's a price: the interleukin-2 was injected twice daily for five days every eight weeks, during which...
...effacing whimsy. Like every good researcher--and every responsible science journalist--he knows all too well that most drugs that work in lab animals turn out to be duds in humans. The field is littered with "magic bullets" that failed, among them monoclonal antibodies, tumor necrosis factor, interferon and interleukin-2. While all were initially hyped as potential cure-alls, they have turned out to have only modest usefulness in the war on cancer. At best, says Dr. Allen Oliff, Merck & Co.'s chief of cancer research, no more than 10% or 20% of agents tried in mice succeed...
...weathered his share of scientific catfights. A brilliant scientist, he is the author or co-author of more than 1,000 scientific papers and one of the world's most frequently cited researchers. In the 1970s, while at the National Cancer Institute, he discovered the immune-boosting molecule interleukin-2 and isolated the first cancer-causing retroviruses in humans...